<DOC>
	<DOC>NCT00002145</DOC>
	<brief_summary>PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy. SECONDARY: To determine frequency of and time to recurrence of gastrointestinal symptoms, response rate of pathological lesions, and incidence of nongastrointestinal CMV disease in this patient population.</brief_summary>
	<brief_title>Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease</brief_title>
	<detailed_description>Patients receive intravenous foscarnet either as induction only for 4 weeks or as induction for 4 weeks followed by maintenance for 22 weeks. All patients are followed for 26 weeks or until relapse.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Patients must have: AIDS. CMV GI disease. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: NonGI CMV disease. Ulcerative colitis, inflammatory bowel disease, or other condition that may interfere with study results. Other GI pathogens. Concurrent Medication: Excluded: Drugs that may interact with foscarnet. Systemic acyclovir, ganciclovir, or acyclovir prodrug. Drugs known to affect renal function. Prior Medication: Excluded: Prior foscarnet in extremis. Investigational agents other than 3TC or d4T within 7 days prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>